~~<i id='8CE365E4A5'><strike id='8CE365E4A5'><tt id='8CE365E4A5'><pre id='8CE365E4A5'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：comprehensive 2025-09-28 02:00:48 Page View：4229

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： I learned firsthand about improving diversity in clinical trials
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Hospitals struggle to profit from CAR

MedicaregenerallypaysfarmoreforCAR-Tdrugsthatareadministeredinoutpatientdepartmentsthanitdoesforinpa

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

SurveillancevideoofPhilanaHolmesreachingfortwoHappyMealsinthedrive-thruatMcDonald'sisshownonacourtro